Viking reports positive maintenance data for obesity drug VK2735Sep 22Clinical readoutViking Therapeutics, Inc.
Kailera reports Q2 2026 results, oral IND active, Phase 2b fully enrolledAug 12Quarterly updateKailera Therapeutics, Inc.
MBX Biosciences reports Q2 2026 results, canvuparatide Phase 3 recruitingAug 6Clinical readoutcanvuparatideMBX Biosciences
Amphastar hits BAQSIMI sales milestone, triggering $100 million payment to LillyAug 6Quarterly updateAmphastar Pharmaceuticals, Inc.Eli Lilly
Amylyx completes LUCIDITY dosing period, sets late-August/early-September readoutAug 6Quarterly updateAmylyx Pharmaceuticals, Inc.avexitide
OPKO reports Q2 2026 results with multiple pipeline milestones across ModeX and OPKO BiologicsJul 27Quarterly updatecalcifediolOPKO Health, Inc.
MetaVia completes dose titration in Phase 1 obesity trial of DA-1726Jul 9Clinical readoutMetaVia Inc.
Sign inSign in